What does debt issuance cost amortization mean?

Non-cash amortization of capitalized costs incurred to issue debt (underwriting fees, legal costs, SEC filing fees).

Syndax Pharmaceuticals SNDX Debt Issuance Cost Amortization

Nuvation BioNUVB

$321K—

Ligand PharmaceuticalsLGND

$803K+490%

Revenue$64.9M+224%

Operating income-$34.2M+59.2%

Net income-$42.7M+49.7%

EPS (diluted)-$0.48+51.0%

Cash & equivalents$130.9M-15.0%

Total debt$350.5M+4.2%

Total equity$41.6M-80.6%

Total assets$472.7M-26.2%

Operating cash flow-$50.3M+47.1%

CapEx$46.8K—

Free cash flow-$80.8M-17.6%

Market cap$1.77B+95.0%

Operating margin-102.8%-47.8pp

Net margin-111.9%-51.5pp

FCF margin-187.2%-85.4pp

Return on equity-189.5%-8,509pp

Debt / equity8.4×+6.9×

Current ratio5.5×-0.3×

Reported directly by Syndax Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.

The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Syndax Pharmaceuticals's debt issuance cost amortization?: Syndax Pharmaceuticals (SNDX) reported debt issuance cost amortization of $56K in Q1 2026.
How has Syndax Pharmaceuticals's debt issuance cost amortization changed year-over-year?: Syndax Pharmaceuticals's debt issuance cost amortization decreased by 50.0% year-over-year, from $112K to $56K.
What does debt issuance cost amortization mean?: Non-cash amortization of capitalized costs incurred to issue debt (underwriting fees, legal costs, SEC filing fees).